Testing a new HIV-waking compound in blood samples from adults with HIV
Blood samples from adults with HIV are used to test a new compound.
Plain-language title generated from the registry record
Registry title: Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Key facts
- Where
- Montpellier, FranceSee the site
Where in France
- CHU de MontpellierMontpellier, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT06441123
- Record updated
- 24 February 2025
- Original description
Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV.Read full original descriptionShow less
Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV.
One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase).
Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.
Inclusion: Patient aged 18 years or older; HIV-positive; On ART (antiretroviral therapy); HIV-1 RNA undetectable for more than 12 months; Nadir CD4 count < 200/µL.
Exclusion: History of cancer less than 5 years old; Lack of antiretroviral treatment; Immunosuppressive treatments; Pregnant or breast-feeding women; Persons protected by law (under guardianship or curators), persons under court protection; Participating in another research project with an ongoing exclusion period; Refusal to participate in research; Subject not affiliated to a social security scheme, or not benefiting from such a scheme.